Activity Overview
Over the past decade, the treatment landscape for advanced HR-positive, HER2-negative breast cancer has been transformed by the combined use of CDK4/6 inhibitors with endocrine therapy (ET). Yet, there is a continuing need for novel ETs that improve treatment outcomes and overcome therapeutic resistance.
This program convenes leading experts to critically examine the latest data on novel ETs and to bridge the gap between the evidence and clinical decision-making. Their discussions focus on current uses for oral selective estrogen receptor degraders (SERDs), as well as emerging roles of next-generation agents, including new drug classes, combination approaches, and use of oral SERDs for early-stage disease. These discussions are presented in the Medical Crossfire® format, designed to illustrate how the faculty approach challenging decision points in their practices.
This educational activity is an archive of the live virtual symposium held on March 7, 2026.
Target Audience
This educational activity is directed toward oncologists, advanced practice professionals, nurses, pharmacists, and other health care practitioners who manage patients with HR+/HER2– metastatic breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement evidence-based strategies for timely biomarker testing, including ctDNA, to optimize the detection and management of ESR1 mutations in HR+/HER2– breast cancer
- Evaluate recent clinical trial data on emerging oral SERDs to inform individualized therapeutic decision-making in HR+/HER2– breast cancer
- Develop multidisciplinary strategies to effectively manage treatment-related adverse events associated with oral SERD therapies in HR+/HER2– breast cancer
VK Gadi, MD, PhD
Professor and
Director of Medical Oncology
Division of Hematology and Oncology
University of Illinois College of Medicine
Associate Director, Translational Oncology
University of Illinois Cancer Center
Chicago, IL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Genentech, Gilead Sciences, Hologic, Novartis, Pfizer, Stemline Therapeutics; Grant/Research Funding: Agendia, AstraZeneca, Gilead Sciences, GSK, Illumina, Novartis; Stock: Tempus
Neil M. Iyengar, MD
Associate Professor, Department of Hematology and Medical
Oncology
Co-Director, Breast Medical Oncology, Department of
Hematology and Medical Oncology
Director, Cancer Survivorship Services
Emory University School of Medicine
Winship Cancer Institute
Atlanta, GA
Disclosures: Consultant/Advisor: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics; Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health; Editorial Position: npj Breast Cancer; Equity/Ownership: Complement Theory, Bettering Company; Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat’s Ribbon of Hope, National Cancer Institute/National Institutes of Health; Contracted Research: Novartis, SynDevRx
Heather McArthur, MD, MPH
Professor, Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, TX
Disclosures: Consultant: Amgen, Arvinas, AstraZeneca, Bristol Myers Squibb, Calithera, Celgene, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Peregrine, Pfizer, Puma, Seattle Genetics, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, TapImmune; Grant/Research Support: Bristol Myers Squibb, BTG, MedImmune/AstraZeneca, Merck
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
